While presenting the data at this year's American Society of Clinical Oncology (ASCO) annual meeting, Peter Voorhees, MD, of ...

"A diagnostic biomarker for IBD would be very impressive, but it would be even more impressive if we had a good biomarker ...

The most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology | Lineage Cell Therapeutics) Catalyst: Invited six-month ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Nebius lags CoreWeave in scale but boasts strong cash, low leverage, and diversified growth across industries. Find out why ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...